Ireland's Health Service Executive (HSE) has detected high-risk synthetic cannabinoids in vape liquids and edible products sold in retail shops and illicit markets [1].
These findings signal a significant public health risk because synthetic cannabinoids are linked to severe physical and mental health harms. The discovery has prompted the HSE's early-warning system to alert both the general public and medical professionals to the presence of these dangerous substances [1, 2].
The substances were found across a variety of formats, including vape "juice," liquid vapes, and other cannabinoid products [1, 3]. According to the HSE, 12 products contained cannabis or related compounds [3], while 41 products were found to contain CBD [3].
The HSE's monitoring system identified these products in both official retail environments and the underground market [1, 2]. This widespread availability suggests that consumers may be unknowingly purchasing high-risk synthetics under the guise of standard vaping products.
Dr. Brian O'Mahony, a senior registrar in psychiatry, has criticized the current approach to managing these substances. He said the government's policy on cannabinoids was "ineffective" [1].
Health officials are urging caution for those using cannabinoid-based products. The synthetic nature of these compounds means they often behave unpredictably in the human body, potentially leading to acute toxicity or psychiatric crises [1, 2].
“High-risk synthetic cannabinoids were detected in vape liquids, vape ‘juice’, and other cannabinoid products.”
The presence of synthetic cannabinoids in legal retail spaces indicates a failure in product regulation and a growing gap between legislation and the illicit market. Because these synthetics are designed to mimic THC but often possess higher potency and toxicity, their availability in common vape shops increases the likelihood of accidental overdose and emergency psychiatric admissions.
